{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:36Z","timestamp":1790712756430,"version":"4.1.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in patients treated with chemoimmunotherapy remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early end point, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At a median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each; P = .4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median 3.3 vs 8.8 years; hazard ratio [HR], 2.8; P = .0036) and OS (HR, 2.6; P = .036) compared with CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS, 71% vs 86%; HR, 3.1; P = .005) and higher mortality (standardized mortality ratio [SMR], 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR, 1.1). In conclusion, BR is effective irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Patients without POD24 represent a cohort with distinctly favorable outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017751","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T21:21:53Z","timestamp":1767820913000},"page":"2322-2327","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["POD24 is a novel determinant of prognosis in patients with Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-6252","authenticated-orcid":false,"given":"Jithma","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"2University College London Hospitals Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, POEMS and Related Conditions, Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[{"name":"3Hematology Department, Sorbonne Universit\u00e9 H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re Assistance Publique - H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-2124","authenticated-orcid":false,"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"4Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-8900","authenticated-orcid":false,"given":"Colin L.","family":"Colby","sequence":"additional","affiliation":[{"name":"4Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University Hospital of Reims and Unit\u00e9s de Formation et de Recherche M\u00e9decine, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"6Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8498-3408","authenticated-orcid":false,"given":"Encarl","family":"Uppal","sequence":"additional","affiliation":[{"name":"2University College London Hospitals Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, POEMS and Related Conditions, Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-2906","authenticated-orcid":false,"given":"Oliver","family":"Tomkins","sequence":"additional","affiliation":[{"name":"2University College London Hospitals Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, POEMS and Related Conditions, Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-3144","authenticated-orcid":false,"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[{"name":"7Department of Hematology, H\u00f4pital Schaffner, Lens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-3757","authenticated-orcid":false,"given":"Patrizia","family":"Mondello","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3854-4209","authenticated-orcid":false,"given":"Lydia","family":"Montes","sequence":"additional","affiliation":[{"name":"8Service d\u2019H\u00e9matologie Biologique, Centre Hospitalier Universitaire de Reims Amiens, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"10Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-1076","authenticated-orcid":false,"given":"Olabisi","family":"Ogunbiyi","sequence":"additional","affiliation":[{"name":"2University College London Hospitals Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, POEMS and Related Conditions, Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-6722","authenticated-orcid":false,"given":"Pascale","family":"Cornillet-Lefebvre","sequence":"additional","affiliation":[{"name":"11Laboratory of Hematology, University Hospital of Reims and UFR M\u00e9decine, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-3442","authenticated-orcid":false,"given":"Anne","family":"Quinquenel","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University Hospital of Reims and Unit\u00e9s de Formation et de Recherche M\u00e9decine, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"6Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"13Department of Medicine, Korea University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven","family":"Treon","sequence":"additional","affiliation":[{"name":"10Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"10Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"9","key":"2026041408011899800_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"2026041408011899800_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m's macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041408011899800_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2023.04.003","article-title":"Frontline management of Waldenstr\u00f6m macroglobulinemia with chemoimmunotherapy","volume":"37","author":"Kapoor","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026041408011899800_bib4","first-page":"02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"22","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2026041408011899800_bib5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2026041408011899800_bib6","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/bjh.19409","article-title":"Long-term results of Waldenstr\u00f6m macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"204","author":"Laribi","year":"2024","journal-title":"Br J Haematol"},{"issue":"21","key":"2026041408011899800_bib7","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.23.02066","article-title":"Simplified Risk Stratification Model for Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"42","author":"Zanwar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041408011899800_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026041408011899800_bib9","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m's macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m's macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026041408011899800_bib10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026041408011899800_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026041408011899800_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/hematology.2024000662","article-title":"The POD24 challenge: where do we go from here for early progressors?","volume":"2024","author":"Mondello","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"2026041408011899800_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2026041408011899800_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"issue":"23","key":"2026041408011899800_bib15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026041408011899800_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m's macroglobulinemia: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2026041408011899800_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2026041408011899800_bib18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026041408011899800_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2025.04.001","article-title":"Report of consensus Panel 3 from the 12th International Workshop on Waldenstr\u00f6m's macroglobulinemia on the management of patients with high-risk disease","volume":"62","author":"Kapoor","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"2026041408011899800_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/hon.2996","article-title":"Does early disease progression predict survival after first line-treatment of Waldenstr\u00f6m macroglobulinemia?","volume":"40","author":"Labreuche","year":"2022","journal-title":"Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2322\/2511622\/blooda_adv-2025-017751-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2322\/2511622\/blooda_adv-2025-017751-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:25Z","timestamp":1776168085000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2322\/565887\/POD24-is-a-novel-determinant-of-prognosis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017751","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,3,30]]}}}